



Press release

SHL announces new Chief Technology Officer

Tel Aviv / Zurich, 6 January 2017 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, today announced that Mr. Yoni Dagan will become the company’s new Chief Technology Officer (CTO) as of 11 February 2017.

Yoni Dagan will be joining SHL Telemedicine from US-based medCPU, a company which’s enterprise decision support software and services captures and analyses the clinical picture from clinicians’ free-text notes, dictations, and structured documentation entered into any Electronic Medical Record. At medCPU, Yoni Dagan was leading the R&D group based in Tel Aviv of over 30 engineers including R&D, integration, QA and algorithms teams. He has over 15 years of experience as a technology expert specializing in medical devices, multidisciplinary systems, and leading multidisciplinary projects. Prior to his role with medCPU, he served as Vice President of R&D in PulmOne Advanced Medical Devices, and CTO in SleepRate leading teams that developed novel medical devices and technologies. Yoni Dagan holds an MSc and a BSc in biomedical engineering, and an MBA from Tel Aviv University. He is a member of the medical devices standardization committee in the Israeli Institute of Standards.

Yuval Shaked, CEO of SHL, said: “Yoni Dagan is a well-respected technology leader in the medical and healthcare space, with depth of knowledge and expertise in many aspects of the clinical treatment of patients. He also has a strong track record of helping businesses take full advantage of the commercial potential of their proprietary know-how and innovative platforms. We are thrilled to have Yoni join us as we continue to execute on our ambitious goal to become a global leader in the telemedicine market.”

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit the web site at www.shl-telemedicine.com.

For further information, please contact:

Martin Meier-Pfister, IRF Communications, phone: +41 43 244 81 40, shl@irfcom.ch

Ehud Ben-Yair, CFO, ehudb@shl-telemedicine.com

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.